Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $4.59 USD
Change Today +0.15 / 3.38%
Volume 20.0K
TTNP On Other Exchanges
As of 5:10 PM 11/27/15 All times are local (Market data is delayed by at least 15 minutes).

titan pharmaceuticals inc (TTNP) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/29/15 - $10.00
52 Week Low
12/30/14 - $2.48
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

titan pharmaceuticals inc (TTNP) Related Businessweek News

No Related Businessweek News Found

titan pharmaceuticals inc (TTNP) Details

Titan Pharmaceuticals, Inc., a specialty pharmaceutical company, develops proprietary therapeutics for the treatment of serious medical disorders in the United States. The company is developing Probuphine for the long term maintenance treatment of opioid dependence. Its Probuphine is designed to maintain a stable, around the clock blood level of the medicine buprenorphine in patients for six months following a single treatment; and utilizes ProNeura, a novel, proprietary, and long-term drug delivery technology. The company’s ProNeura is also used in developing products for the treatment of other chronic conditions, such as Parkinson’s disease. It is also developing Fanapt (iloperidone), an atypical antipsychotic for the treatment of schizophrenia. The company was founded in 1992 and is based in South San Francisco, California.

13 Employees
Last Reported Date: 03/31/15
Founded in 1992

titan pharmaceuticals inc (TTNP) Top Compensated Officers

President, Secretary and Director
Total Annual Compensation: $300.0K
Executive Chairman and Member of Executive Co...
Total Annual Compensation: $210.0K
Compensation as of Fiscal Year 2014.

titan pharmaceuticals inc (TTNP) Key Developments

Titan Pharmaceuticals Inc. Announces Earnings Results for the Third Quarter and Nine Months Ended September 30, 2015

Titan Pharmaceuticals Inc. announced earnings results for the third quarter and nine months ended September 30, 2015. For the quarter, the company reported loss from operations of $1.8 million compared to a loss from operations of $738,000 for the same quarter ended September 30, 2014. For the nine months, net loss and comprehensive loss was $8.98 million or $0.45 loss per diluted share compared to a net loss and comprehensive loss of $1.93 million or $0.14 loss per diluted share for the same period ended September 30, 2014. Loss from operations was $4.51 million, compared to a loss from operations of $2.22 million for the same period ended September 30, 2014.

Titan Pharmaceuticals Inc. Announces Earnings Results for the Third Quarter of 2015

Titan Pharmaceuticals Inc. announced earnings results for the third quarter of 2015. The company recognized no revenue in the third quarter of 2015 compared with approximately $0.9 million of revenue recognized in the third quarter of last year, which consisted of license revenue and reflected the amortization of the upfront license fee received from Braeburn in December 2012. Net loss for the 2015 third quarter was approximately $1.8 million or about $0.09 per share compared with net income of about $0.7 million or approximately $0.04 per share in the same period in 2014.

Titan Pharmaceuticals, Inc. Adds Implantable Triiodothyronine (T3) Product for the Treatment of Hypothyroidism to its Product Development Pipeline

Titan Pharmaceuticals Inc. announced that it has added an implantable triiodothyronine (T3) product for the treatment of hypothyroidism to its product development pipeline. ProNeura-T3 could potentially offer significant advantages over once-daily oral delivery for patients who need T3 in their treatment regimen. Titan's ProNeura drug delivery technology is being developed for select chronic disease for which the low dose, continuous delivery of medication could offer health and safety benefits over oral delivery. The company's lead product candidate, Probuphine, is being developed for the long-term maintenance treatment of opioid addiction. The U.S. Food and Drug Administration has accepted for review a New Drug Application (NDA) for Probuphine and has set an action date of February 27, 2016 on the NDA. Titan is also developing a ProNeura implant containing ropinirole, a dopamine agonist, for the treatment of Parkinson's disease and expects to commence clinical testing of this product candidate by the end of next year.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TTNP:US $4.59 USD +0.15

TTNP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alkermes PLC $75.60 USD +1.54
Reckitt Benckiser Group PLC 6,309 GBp -37.00
View Industry Companies

Industry Analysis


Industry Average

Valuation TTNP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 35.6x
Price/Book 10.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 31.9x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact TITAN PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at